Hassan Ashktorab to Enzyme Inhibitors
This is a "connection" page, showing publications Hassan Ashktorab has written about Enzyme Inhibitors.
Connection Strength
0.158
-
Rath S, Das L, Kokate SB, Ghosh N, Dixit P, Rout N, Singh SP, Chattopadhyay S, Ashktorab H, Smoot DT, Swamy MM, Kundu TK, Crowe SE, Bhattacharyya A. Inhibition of histone/lysine acetyltransferase activity kills CoCl2-treated and hypoxia-exposed gastric cancer cells and reduces their invasiveness. Int J Biochem Cell Biol. 2017 01; 82:28-40.
Score: 0.122
-
Xu C, Ooi WF, Qamra A, Tan J, Chua BY, Ho SWT, Das K, Adam Isa ZF, Li Z, Yao X, Yan T, Xing M, Huang KK, Lin JS, Nandi T, Tay ST, Lee MH, Tan ALK, Ong X, Ashktorab H, Smoot D, Li S, Ng SC, Teh BT, Tan P. HNF4a pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer. Gut. 2020 02; 69(2):231-242.
Score: 0.036